? analogue (KP1339) are two of the most prominent non-platinum antitumor metal complexes currently undergoing clinical trials. After intravenous administration, they are known to bind to human serum albumin (HSA) in a noncovalent manner. To elucidate their HSA binding sites, displacement reactions with the established site markers warfarin and dansylglycine as well as bilirubin were monitored by spectrofluorimetry, ultrafiltration-UV-vis spectrophotometry, and/or capillary zone electrophoresis. Conditional stability constants for the binding of KP1019 and KP1339 to sites I and II of HSA were determined, indicating that both Ru(III) compounds bind to both sites with moderately strong affinity (log K 1 0 = 5.3-5.8). No preference for either binding site was found, and similar results were obtained for both metal complexes, demonstrating low influence of the counter ion on the binding event.
Introduction
The field of metal-based anticancer drugs was initiated by the discovery of cisplatin, one of the leading agents in clinical use [1] . Ruthenium compounds are currently considered the most likely candidates for the next generation of metal-based anticancer drugs [2, 3] . Two representatives Electronic supplementary material The online version of this article (doi:10.1007/s00775-012-0944-6) contains supplementary material, which is available to authorized users. of this class of compounds have entered clinical trials so far: imidazolium trans-[tetrachlorido(dimethyl sulfoxide)(1H-imidazole)ruthenate(III)] (NAMI-A) [4, 5] and indazolium trans-[tetrachloridobis(1H-indazole)ruthenate (III)] (KP1019) [6] [7] [8] (see Fig. 1 for structures). Only very moderate toxicities were observed in the case of KP1019 [6, 7, 9] , whereas NAMI-A treatment was accompanied by painful blister formation determining the maximum tolerated dose [10] .
KP1019 shows remarkable antineoplastic activity against a wide number of preclinical tumor models, including cisplatin-resistant colorectal tumors and some primary explanted human tumors [2, 6, 11, 12] . Although the pharmacological target for antitumor ruthenium compounds has not been unequivocally identified, it is unlikely that their modes of action are similar to that of cisplatin [7] . The limitation in the application of KP1019 in clinics was the low solubility and, therefore, the maximum tolerated dose was not reachable in clinical trials [8] . According to the clinical study, the maximum plasma level was about 0.3 mM for KP1019 [8] . The problem of low solubility was solved by the replacement of the indazolium counter ion by sodium (KP1339; Fig. 1 ). KP1339 is significantly better water soluble than KP1019 and is being investigated in an ongoing clinical trial.
The minor side effects of the Ru(III) compounds may be related to their modes of action. After intravenous administration, the complex binds to highly abundant serum proteins such as human serum albumin (HSA) and transferrin [13] [14] [15] . The selective tumor targeting can be realized by the enhanced permeability and retention effect of the tumor tissue, and by the overexpression of transferrin receptors on cancer cells [16] . A further reason for their selectivity is the insufficient formation of new blood vessels in rapidly growing tumors that results in a more reductive environment as compared with normal tissue and facilitates reduction of Ru(III) to Ru(II) (''activation by reduction'' hypothesis) [17] [18] [19] and therefore ligand exchange and coordination with biological targets such as DNA and proteins [7, 12, 20] .
Therefore, reactions of anticancer metallodrugs with proteins are of considerable interest as these interactions might feature processes that are crucial for the biodistribution, the toxicity, and even the mechanism of action of this important group of anticancer agents. KP1019 is known to bind to a large degree to HSA, which was suggested to act as a ruthenium reservoir [15, 21, 22] . HSA is the most abundant of the blood serum proteins, occurring to the extent of 0.63 mM. It contributes to colloid osmotic pressure and is chiefly responsible for the maintenance of blood pH. The protein serves as a transport vehicle for a wide variety of ligands, including fatty acids, bilirubin (BR), steroids, metal ions, and various pharmaceuticals. It comprises a single chain with 585 amino acids organized in three similar domains (I, II, and III), each consisting of two subdomains (IA, IB, etc.). The principal regions of the ligand binding sites of HSA are located in hydrophobic cavities in subdomains IIA and IIIA (sites I and II) [23] [24] [25] . A typical site marker for site I is the anticoagulant drug warfarin (WF) [26] [27] [28] [29] , whereas dansylglycine (DG) shows specificity for site II (see Fig. S1 ) [30] [31] [32] . Initial rapid binding of KP1019 occurs in a noncovalent manner at the hydrophobic binding sites of HSA; however, after a longer incubation time the type of the interaction slowly changes to a protein-coordinated form [33] . Similar behavior of NAMI-A and its pyridine analogues was found recently on the basis of mainly electron paramagnetic resonance spectroscopic measurements [34, 35] . A binding ratio of four KP1019 complex anions to a single HSA molecule was determined by circular dichroism spectroscopy and was confirmed by inductively coupled plasma atomic emission spectroscopy [23] . More recently, the KP1019-HSA association constants were determined by means of capillary electrophoresis (CE) as 9.9 9 10 3 M -1 , and by CE coupled with inductively coupled plasma mass spectrometry as 1.06 9 10 4 M -1 [13, 21] . It is noteworthy that separation methods such as CE may shift the chemical equilibrium of a reaction mixture, and therefore spectroscopic methods provide a better means to investigate binding constants. Furthermore, the actual binding sites of KP1019 on HSA remain elusive. Herein, we report on displacement experiments by means of spectroscopic and separation methods with well-established site markers for sites I and II and with the heme metabolite BR (Fig. S1 ), which is also transported by HSA and has relevance for patients with hyperbilirubinemia [36] .
Results and discussion
Ru(III) complexes are known to undergo hydrolysis in aqueous solution [37, 38] , with the kinetics being dependent on the pH and the chloride concentration in the incubation medium [37] . Human plasma has a pH of about 7.4 and the chloride concentration is 104 mM. To suppress the hydrolysis to a wide extent, a chloride concentration of 150 mM was chosen in our experiments and the incubations were done in 20 mM phosphate buffer (pH 7.40). This approach was successful for other anticancer agents such as cisplatin and Ru(II)-arene complexes [39] [40] [41] [42] . However, the chloride/water exchange in KP1019 and KP1339 is not suppressed completely within a 1-h interval under these conditions (25°C, pH 7.40, 150 mM Cl -) (Fig. S2) , and especially in the case of KP1019, more aquation occurs (after 1 h, about 9 %).
It is noteworthy that the recovery of HSA from human blood and its dissolution in water and use under aerobic conditions can easily lead to the oxidation of the free thiol group of the cysteine-34 residue. Thus, HSA is most probably at least partially present in the dimeric form. The dimerization may alter the binding capacities [43] , but as the level of dimerization is unknown, the average binding capacity of the monomeric and dimeric HSA were calculated.
Initially, the conditional stability constants for the reaction of the Ru(III) complexes KP1019 and KP1339 with HSA were determined by means of fluorescence spectroscopy. HSA contains a single tryptophan (Trp214) residue that is responsible for most of the intrinsic fluorescence of the protein. Upon excitation at 295 nm, HSA fluoresces strongly at 350 nm, which can be attenuated by a binding event at or close to Trp214 owing to its susceptibility to changes in its environment. Addition of KP1339 to HSA quenches its fluorescence very efficiently (Fig. 2) , indicating that the conformation of the hydrophobic binding pocket in site I is significantly affected by the Ru(III) complex binding. Because self-absorption of these complexes is significant at the wavelength range of the quenching measurements and would interfere with modeling (Table 1) , a correction equation was applied to minimize this effect (see ''Spectrofluorimetric measurements''). Trynda-Lemiesz et al. [22] also observed the quenching of the emission of tryptophan by KP1019; however, under the conditions applied, the samples showed high absorbance and no binding data were reported. The conditional stability constants calculated using the SternVolmer approach for KP1339 at a chosen emission wavelength (inset of Fig. 2b ) and with PSEQUAD [44] for both complexes using the whole spectra were found to be similar (Table 1) . Graphical solutions such as the Stern-Volmer plot, which is widely used in the literature [45, 46] , cannot be applied in the emission wavelength range if the ligand has significant intrinsic emission, such as for the indazolium counter cation in KP1019 with an excitation wavelength of 295 nm (see Figs. S3, S4; KP1339 is not fluorescent). Experiments to elucidate the role of the indazolium ion in the binding of KP1019 and HSA revealed only weak binding of indazole to site II, and no binding to site I. Another critical point of the Stern-Volmer approach is that the substitution of the equilibrium concentrations by analytical concentrations in the formula may not provide trustworthy stability constants. The conditional binding constants log K 0 under these conditions were computed from the quenching studies as 4.69 (6) and 5.66 (6) for KP1339 and KP1019, respectively. This big difference between the two binding constants has no reasonable chemical explanation but there are methodological uncertainties. To elucidate the problem, the direct interaction between HSA and complexes KP1019 and KP1339 was also followed by ultrafiltration quantification measurements with UV-vis spectrophotometric quantification.
It is noteworthy that ultrafiltration might induce release of weakly surface bound ligands. In this setup, the nonbound fraction was separated from HSA and the HSARu(III) complex by ultrafiltration with a 10 kDa cutoff membrane filter, resulting in low molecular mass (LMM) and high molecular mass (HMM) fractions. The LMM samples were analyzed by UV-vis spectroscopy and their spectra were compared with reference spectra (see Fig. S5 for the HSA-KP1339 system), yielding the ratios of the nonbound and total amount of the compounds. From these data pairs, the stoichiometry and conditional stability constants of the HSA complexes were calculated (Fig. 3 , Table 1 ). This method allows the determination of stepwise stability constants, whereas spectrofluorimetry can only be used for the first step because of the highly diluted samples, resulting in strong dissociation. Comparing the log K 1 0 values calculated by the different methods, one can see that ultrafiltration-UV-vis spectrophotometry gave somewhat lower values than spectrofluorimetry. The main reason is probably the different experimental conditions of the methods used: interference in the equilibrium during the separation process in ultrafiltration and micromolar concentrations in spectrofluorimetry, and millimolar concentrations in ultrafiltration in the quantification process.
In recent years, researchers have become interested in determining the binding sites of metallodrugs on biomolecules for improved design of next-generation drug candidates. It is known that KP1019 binds to HSA initially in a noncovalent manner, and then the coordination of histidine nitrogen(s) to the Ru(III) center occurs [33] . The spectrofluorimetric quenching studies and the ultrafiltration (vide supra) cannot give information on whether the binding mode is noncovalent or coordinative. To obtain deeper insight into the binding event, a strategy involving particular site markers was applied to probe the nature of the preferred binding site, as well as the specificity and affinity for the protein.
WF and BR were used as site markers for site I, and DG was used as a site marker for site II; Fig. 4 demonstrates that these compounds have weak or negligible molar fluorescence at the given excitation wavelengths. The addition of HSA induced an increase in intensity owing to the binding of these compounds to the respective site on the protein. On the basis of the molar fluorescence spectra, which are only valid under the conditions and instrument settings applied, stability constants were calculated using PSEQUAD [44] . The conditional HSA binding constants (log K 0 ) for WF, BR, and DG are comparable with data obtained by us and others [26-32, 36, 47, 48] (Table S1) , and are practically temperature-independent (25 vs. 37°C) within the uncertainty of the measurement. The calculations for BR required application of a self-absorbance correction because of its considerable absorbance at the excitation wavelength. However, the Ru(III) complexes and their HSA adducts [HSA-Ru(III) complex] have no intrinsic emission in this wavelength range.
The HSA-site marker adducts HSA-WF, HSA-BR, and HSA-DG emit intensively and their displacement by other ligands from the binding pocket of the protein is accompanied by a considerable decrease in the emission intensity. Therefore, the displacement of the site markers at various concentrations of the Ru(III) complexes could be followed via intensity changes of the emission spectra. In case of the HSA-WF-KP1339 system, the initial intensity decreased by about 50 % upon addition of an eightfold excess of the Ru(III) complex (Fig. 5) , accompanied by a bathochromic shift, which can be attributed to the increasing free WF fraction and its higher emission maximum. Similar results were obtained for the reaction of KP1019 and HSA-WF, and the binding constants calculated from WF displacement and quenching measurements (Table 1 ) are in good agreement.
The displacement reactions of BR and DG displayed a similar trend as found for WF (for DG, see Fig. 6 ), and no significant difference for KP1019 and KP1339 was observed (for the conditional stability constants, see Table 1 ). On the basis of these data, it can be concluded that the nature of the counter ion does not affect the ability of the trans-[tetrachloridobis(1H-indazole)ruthenate(III)] anion to interact with HSA. However, in the case of KP1339, the constant derived from the quenching experiments is one order of magnitude lower than that obtained from WF displacement, whereas in the case of KP1019, similar results were obtained. Although it can happen that a small portion of KP1339 loses the axial indazole ligand and since the free ligand has extremely strong emission for 295-nm excitation wavelength, this can cause less quenching of the HSA fluorescence. It is noteworthy that the displacement of WF and BR by KP1019 was also observed previously; however, no quantitative data evaluation was performed [22] .
In addition to the spectroscopic studies, the reactions of the HSA-Ru(III) complex with WF and DG were studied by capillary zone electrophoresis (CZE)-UV-vis and ultrafiltration-UV-vis methods (BR could not be studied because of its low aqueous solubility and molar absorbance). CE has been used to determine chemical equilibria in protein-metallodrug systems [49, 50] . Compared with other separation-based assays such as high-performance liquid chromatography, CE has distinctive advantages, such as shorter analysis time, use of electrolyte compositions compatible with physiological incubation conditions, and no stationary phase involved in separation [51] . A similar approach as in the spectroscopic studies was followed, with the HSA-to-site marker ratio kept constant and the KP1019 and KP1339 content was varied. No interaction between the Ru(III) compounds and the site markers was detected by CZE under the conditions applied, and a linear concentration-peak height correlation was observed for the metal complexes (Figs. S6, S7 ). The data were analyzed on the basis of the increase of the peak heights for the released site markers as a result of their displacement by the Ru(III) complexes [48] . Figure 7 shows the displacement of WF by the Ru(III) complexes monitored by CZE. The increasing amount of the nonbound site marker with increasing metal complex concentration confirms that these complexes tend to compete with WF for the HSA binding sites and the same tendency was observed in the case of DG. Moreover, an eightfold excess of the complexes was sufficient to complete the displacement of the site markers at a 1:1 site marker to HSA ratio. Again, very similar behavior for the two Ru(III) complexes was observed with the ultrafiltration displacement approach. Analysis of the LMM fraction by spectrofluorimetry and the UV-vis method revealed an increasing quantity of nonbound site marker with higher metal complex concentration (see Fig. S8 ). This indicates that both KP1339 and KP1019 are able to compete with WF and DG for the respective HSA binding sites with similar binding strength and to a similar extent.
An important feature for the clinical application of such drug compounds may be the fact that both Ru(III) complexes can displace BR from HSA (Fig. 8) . The unbound fraction of the Ru(III) complex calculated on the basis of the stability constants (Table 1) is increased at higher concentrations of BR in a hypothetical system containing 630 lM HSA (according to its physiological serum concentration) and equimolar KP1339, i.e., an increase of the BR concentration from 11 to 68 lM causes a significant 2.5-fold increase in the free, unbound fraction of the Ru(III) complexes (Fig. 9) . It is noteworthy that all the BR is bound to HSA under these conditions, and no displacement of BR by the Ru(III) complex occurs. Generally the free portion of a drug can reach the final target, and hence is responsible for the biological effect, whereas HSA has potentially a temporary reservoir role [52, 53] . Taking into account that patients with liver malfunctions have higher BR levels, this result may be of significance for their treatment with such Ru(III) complexes.
Conclusions
It is essential to explore the interactions of anticancer metallodrugs with serum proteins as these interactions might feature processes that are crucial for biodistribution, toxicity, and even their mechanism of action. HSA is the most abundant plasma protein and is responsible for the binding and transport of numerous molecules, including metal complexes. The characterization of the binding of the Ru(III) complexes KP1339 and KP1019 to HSA and the determination of the preferred binding sites were performed as this protein is considered their primary binding partner after intravenous administration. A panel of methods comprising spectrofluorimetry, CZE-UV-vis spectrophotometry, and ultrafiltration-UV-vis spectrophotometry were used to investigate the interaction between HSA and KP1019 as well as KP1339. Using WF, BR, and DG as site markers, we determined the preferred binding sites for these novel chemotherapeutics by displacement experiments. Considerable displacement of all site markers occurs upon addition of both Ru(III) compounds, demonstrating their ability to bind to both site I and site II of HSA. No significant differences were found in the binding ability at these binding sites on the basis of the spectrofluorimetric measurements; and both KP1019 and KP1339 are able bind to both sites with moderately strong affinity. Therefore, the counter ion does not affect the binding of trans-[tetrachloridobis(1H-indazole)ruthenate(III)] anions to HSA. CZE-UV-vis and ultrafiltration-UV-vis measurements also confirmed the results of the spectrofluorimetric experiments. A result of clinical relevance is the finding that KP1339 and KP1019 are able to compete with BR for its binding site under physiological conditions and may affect the treatment of patients with elevated BR levels.
Materials and methods

Chemicals
KP1019 and KP1339 were synthesized at the Institute of Inorganic Chemistry of the University of Vienna. Racemic WF, DG, BR, HSA (as lyophilized powder with fatty acids, A1653), NaH 2 PO 4 , Na 2 HPO 4 , and NaCl were obtained from Sigma-Aldrich in puriss quality. Doubly distilled Milli-Q water was used for preparation of samples. .
Spectrofluorimetric measurements
Fluorescence spectra were recorded with a Hitachi-F4500 fluorimeter using a 5 nm/5 nm slit width in a 1-cm quartz cell at 25.0 ± 0.1°C. All solutions were prepared in 20 mM phosphate buffer (pH 7.40) containing 150 mM NaCl and were incubated for 15 min. Samples usually contained 1 lM HSA (10 lM HSA in BR displacement experiments) and various HSA-to-ligand ratios (from 1:0 to 1:20) were used. In the site marker displacement experiments, the HSA to site marker (WF, DG, or BR) ratio was 1:1 and the concentration of the Ru(III) complexes was varied. Spectra were recorded after 10-min incubations. BR-containing samples were kept in the dark. The excitation wavelengths were 295, 310, 335, or 487 nm depending on the type of experiment, and the emission was read in the range 310-650 nm (see Table S2 for details). The conditional binding constants were calculated with the computer program PSEQUAD [44] , and quenching data were also analyzed by Stern-Volmer plots (see the electronic supplementary material) for comparison purposes [45, 46] . Three-dimensional spectra were recorded for 210-500-nm excitation and 230-650-nm emission wavelengths.
A correction for self-absorbance was necessary in the quenching experiments because fluorescence is significantly absorbed by the Ru(III) complexes. Samples containing BR also had to be corrected (for the molar absorption spectra of KP1339 and BR, see Fig. S9 ). The correction was done according to the equation [45] 
where F corrected and F measured are the corrected and measured fluorescence intensities, and A(EX) and A(EM) are the absorptivities at the excitation and emission wavelengths in the samples, respectively. The inner filter effect in the case of other titrations was negligible and therefore no corrections were applied.
Membrane ultrafiltration-UV-vis measurements
Samples were separated by ultrafiltration through 10-kDa membrane filters (Microcon YM-10 centrifugal filter unit, Millipore) in LMM and HMM fractions with the help of a temperature-controlled centrifuge (Sanyo, 10,000 s -1 , 10 min). The samples (0.50 mL) contained 60 lM HSA and the metal complexes (from 10 to 150 lM) in 20 mM phosphate buffer (150 mM NaCl; pH 7.40 at 25.0 ± 0.1°C) and were incubated for 15 min. In the site marker displacement experiments, the HSA to site marker ratio was 1:1 and the concentration of the Ru(III) complexes was varied (from 10 to 180 lM). The LMM fraction containing the nonbound metal complex was separated from HSA and HSA-KP1019 (or HSA-KP1339) adducts in the HMM fraction. The LMM fractions were diluted to 1.00 mL, and the concentration of the nonbound complex was determined by UV-vis spectrophotometry and in the case of competition measurements by spectrofluorimetry (according to the site marker, see the details in Table S2 and Fig. S10 ). The UV-vis spectra of the LMM fractions were compared with the reference spectra of the samples containing KP1019 or KP1339 without the protein at a concentration equal to that in the ultrafiltered samples. A Hewlett-Packard 8452A spectrophotometer was used to record the spectra in the region from 200 to 700 nm at 25°C and with a path length of 1 cm. Stoichiometries and conditional binding constants (log b 0 ) were then calculated on the basis of the equilibrium processes, and mass-balance equations for the components (see the electronic supplementary information) were established with the computer program PSEQUAD [44] from the total and protein-free concentration data pairs of the ligands obtained at different protein to Ru(III) complex ratios; uncertainties in the stability constants are given in parentheses.
CZE measurements
CZE experiments were performed with an HP 3D CZE system (Agilent Technologies). For all experiments capillaries of 48-cm total length (50-lm inner diameter) were used (BGB Analytik). The detection was done by on-column UV photometric measurement in the range from 200 to 330 nm. Injections were performed by applying a pressure of 30 mbar for 5 s, and constant voltages of 28 kV were used for phosphate buffer at pH 7.40 as the background electrolyte (BGE). Prior to the first use, the capillary was flushed at 1 bar with 0.1 M HCl, water, 0.1 M NaOH, and again with water (10 min each). Before each injection, the capillary was purged for 2 min with both water and the BGE, followed by application of a voltage of 28 kV for 30 s and was then flushed with BGE again for 1 min. The cleaning procedure included purging with 0.1 M HCl, water, and 0.1 M NaOH (each for 2 min). The CZE data were recorded using the program ChemStation (Agilent Technologies).
Samples containing 100 lM HSA and the ligands (from 25 to 800 lM) in 20 mM phosphate buffer (150 mM NaCl; pH 7.40 at 25.0 ± 0.1°C) were incubated for 40 min prior to the measurements. In the WF or DG displacement experiments, the HSA to site marker ratio was 1:1 and the concentration of KP1019 or KP1339 was varied (from 25 to 800 lM). The peak height of the nonbound site marker was used in order to obtain its concentration by employing external calibration.
